Summary
Edwards Lifesciences Corporation (EW) announced on May 6, 2003, the pricing of $125 million in 37/8% convertible senior debentures due 2033. The company also has an option to issue an additional $25 million in debentures to cover over-allotments, bringing the potential total to $150 million. These debentures are being offered exclusively to qualified institutional buyers. The filing emphasizes that the press release contains forward-looking statements subject to risks and uncertainties, and actual results could differ materially. Investors should consult the company's SEC filings for a more detailed understanding of these risks.
Key Highlights
- 1Pricing of $125 million in 37/8% convertible senior debentures due 2033.
- 2Potential for an additional $25 million in debentures to be issued for over-allotments.
- 3Debentures offered solely to qualified institutional buyers.
- 4The financing aims to raise capital for the company.
- 5Filing includes standard forward-looking statement disclaimers regarding risks and uncertainties.
- 6The press release attached as an exhibit provides details on the offering.
Frequently Asked Questions
This 8-K filing announces the pricing of a new debt offering by Edwards Lifesciences. Specifically, it details the terms of $125 million of 37/8% convertible senior debentures due 2033, with an option for an additional $25 million.
The debentures are being offered exclusively to qualified institutional buyers. This means individual retail investors are not eligible to participate directly in this offering.
The press release included in the filing contains forward-looking statements that highlight potential risks and uncertainties. These could affect whether the company successfully completes the offering, how it utilizes the proceeds, and other factors detailed in their broader SEC filings. Actual outcomes may differ significantly from management's current expectations.
The 'convertible' feature means that bondholders have the option to convert their debentures into a predetermined number of shares of Edwards Lifesciences' common stock under certain conditions. This can be attractive to investors seeking potential equity upside while maintaining the fixed-income characteristics of a bond.